Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Azienda Ospedaliera, University of Padua, Via Giustiniani, 2, Padua, 35128, Italy.
Intern Emerg Med. 2021 Mar;16(2):419-427. doi: 10.1007/s11739-020-02495-w. Epub 2020 Sep 27.
Patients at greatest risk of severe clinical conditions from coronavirus disease 2019 (COVID-19) and death are elderly and comorbid patients. Increased levels of cardiac troponins identify patients with poor outcome. The present study aimed to describe the clinical characteristics and outcomes of a cohort of Italian inpatients, admitted to a medical COVID-19 Unit, and to investigate the relative role of cardiac injury on in-hospital mortality.
We analyzed all consecutive patients with laboratory-confirmed COVID-19 referred to our dedicated medical Unit between February 26th and March 31st 2020. Patients' clinical data including comorbidities, laboratory values, and outcomes were collected. Predictors of in-hospital mortality were investigated. A mediation analysis was performed to identify the potential mediators in the relationship between cardiac injury and mortality. A total of 109 COVID-19 inpatients (female 36%, median age 71 years) were included. During in-hospital stay, 20 patients (18%) died and, compared with survivors, these patients were older, had more comorbidities defined by Charlson comorbidity index ≥ 3(65% vs 24%, p = 0.001), and higher levels of high-sensitivity cardiac troponin I (Hs-cTnI), both at first evaluation and peak levels. A dose-response curve between Hs-cTnI and in-hospital mortality risk up to 200 ng/L was detected. Hs-cTnI, chronic kidney disease, and chronic coronary artery disease mediated most of the risk of in-hospital death, with Hs-cTnI mediating 25% of such effect. Smaller effects were observed for age, lactic dehydrogenase, and D-dimer.
In this cohort of elderly and comorbid COVID-19 patients, elevated Hs-cTnI levels were the most important and independent mediators of in-hospital mortality.
患 2019 年冠状病毒病(COVID-19)并出现严重临床症状和死亡的高危患者为老年和合并症患者。心肌肌钙蛋白水平升高可识别预后不良的患者。本研究旨在描述一组意大利住院患者的临床特征和结局,并探讨心脏损伤对住院死亡率的相对作用。
我们分析了 2020 年 2 月 26 日至 3 月 31 日期间我院收治的所有经实验室确诊的 COVID-19 连续患者。收集患者的临床数据,包括合并症、实验室值和结局。调查了住院死亡率的预测因素。进行中介分析,以确定心脏损伤与死亡率之间关系的潜在中介因素。共纳入 109 例 COVID-19 住院患者(女性占 36%,中位年龄 71 岁)。住院期间,20 例患者(18%)死亡,与存活者相比,这些患者年龄较大,合并症较多(Charlson 合并症指数≥3 者占 65% vs 24%,p=0.001),且高敏肌钙蛋白 I(hs-cTnI)水平较高,初次评估和峰值时均如此。在 hs-cTnI 和住院死亡率风险之间检测到了 200ng/L 上限的剂量-反应曲线。hs-cTnI、慢性肾脏病和慢性冠状动脉疾病介导了大部分住院死亡风险,hs-cTnI 介导了该效应的 25%。年龄、乳酸脱氢酶和 D-二聚体的影响较小。
在本队列的老年和合并症 COVID-19 患者中,hs-cTnI 水平升高是住院死亡率的最重要和独立的中介因素。